Slide 1: Earnings Call – Q2 2022
Earnings Call – Q2 2022 August 2, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
2©2022 ViewRay Technologies, Inc. All rights reserved. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this presentation that are not purely historical are forward-lookin
Slide 3: Our Mission: Treat and prove what others can't
3©2022 ViewRay Technologies, Inc. All rights reserved. Our Mission: Treat and prove what others can’t. 533 installed globally 25k2 k patients treated ~700 systems in planning or installation ~ Thousands of patients with clinically reported outcomes.
Slide 4: What we achieved – financial results Q2 2022
4©2022 ViewRay Technologies, Inc. All rights reserved. What we achieved – financial results Q2 2022 Q2 2022 Q2 2021 Change MRIdian orders 8 7 14% MRIdian backlog $352.8M $278.4M 27% Revenue $22.1M $15.0M 47% Gross Margin 4.9% -11.1% +1,600 bps Cash use $22.5M $15.1M +7.4m (1) Excluding net proceeds
Slide 5: Strategic pillars driving commercial traction
5©2022 ViewRay Technologies, Inc. All rights reserved. Clinical evidence Innovation Market awareness Strategic pillars Driving commercial traction
Slide 6: Clinical evidence: Treat and prove what others can't
6©2022 ViewRay Technologies, Inc. All rights reserved. Clinical evidence Innovation Market awareness Strategic pillars Mission: Treat and prove what others can’t • In tough-to-treat cancers aim to extend survival ― Dr. Chuong’s Pancreas data demonstrates double survival of conventional therapy • In
Slide 7: Innovation: A3i live, GBM patients treated
7©2022 ViewRay Technologies, Inc. All rights reserved. Clinical evidence Innovation Market awareness Strategic pillars Mission: Treat and prove what others can’t • A3i went live at Henry Ford and Miami Cancer Institute • Customers experiencing workflow enhancements and reduced treatments times • Fir
Slide 8: Market awareness: Katie Couric Media agreement
8©2022 ViewRay Technologies, Inc. All rights reserved. Clinical evidence Innovation Market awareness Strategic pillars Mission: Treat and prove what others can’t • Entered into an agreement with Katie Couric Media to increase MRIdian awareness
Slide 9: Systems in planning or installation
9©2022 ViewRay Technologies, Inc. All rights reserved. Clinical evidence Innovation Market awareness Strategic pillars Mission: Treat and prove what others can’t • ~70 systems in planning or installation • Diverse customer set, including free-standing and community- based medical centers • Customers
Slide 10: Successful MRIdian programs driving adoption
10©2022 ViewRay Technologies, Inc. All rights reserved. Successful MRIdian programs driving adoption Similar markets • Northeast • Upper Midwest • Florida • France • UK • Italy California Future program Active program
Slide 11: In 2022… Delivering P&L leverage
11©2022 ViewRay Technologies, Inc. All rights reserved. In 2022… Meaningful operating expense leverage Placements expected to drive 750 - 1,000 bps of gross margin expansion On track to deliver ~40% revenue growth Well capitalized: sufficient cash on hand to drive to cash flow breakeven Delivering P
Slide 12: Financial Results Q2 2022
> vIEwRAY Financial Results Q2 2022
Slide 13: What we achieved – financial results Q2 2022
13©2022 ViewRay Technologies, Inc. All rights reserved. What we achieved – financial results Q2 2022 (1) Excluding net proceeds from equity offering. (2) Inclusive of restricted cash related to a customer deposit. Q2 2022 Q2 2021 Change MRIdian orders 8 7 14% MRIdian backlog $352.8M $278.4M 27% Reve
Slide 14: 2022 guidance
14©2022 ViewRay Technologies, Inc. All rights reserved. C as h U sa ge R ev en ue CURRENT $90M - $104M (*) Excluding proceeds from equity offerings in 2021 PRIOR $68M - $83M 2022 guidance $84M - $104M $68M - $83M G ro w th 28% - 48% 20% - 48%
Slide 15: ViewRay – Visibly Better
OVIEWRAY VSBL/BETTER VISIBLY BETTER